Psychedelics Stocks: 6 Names Ranked After Lilly's $2.8B Bet

Everyone left psychedelics for dead after the Lykos MDMA-assisted therapy CRL in August 2024. The sector drawdown was brutal: Compass Pathways dropped 75% from its 2021 peak, Cybin shed 85%, and MindMed traded below cash. The bear case was simple: the FDA was hostile, DEA scheduling was unresolved, and the commercial model for therapist-supervised psychedelic sessions had no precedent. Then Lilly paid $2.8 billion for AtaiBeckley in July 2026, and the pendulum swung. Big pharma does not pay eight-figure premiums for assets it thinks regulators will reject. Two months after the deal, Lykos (now Resilient) resubmitted its MDMA NDA in August 2026, and Compass Pathways entered NDA rolling review for COMP360 psilocybin with a Commissioner’s National Priority Voucher. The psychedelics trade is back. Here are six names ranked by catalyst and risk.

1. Compass Pathways (CMPS, $13.73, ~$2.0B market cap): Buy

Catalyst: COMP360 psilocybin NDA rolling review; H1 2027 launch target

Compass is the sector leader and the closest to an FDA approval. COMP360, a proprietary synthetic psilocybin formulation, hit its primary endpoint in a second Phase 3 trial for treatment-resistant depression, building on the first Phase 3 success, which showed a mean treatment difference of -3.6 MADRS points versus placebo (p<0.001) with durability at six months. The FDA granted rolling NDA review and awarded COMP360 a Commissioner’s National Priority Voucher, a signal the agency views this as a meaningful advance over existing TRD therapies (the neuroscience catalysts piece covers the broader CNS picture).

The numbers: TRD affects roughly 3 million Americans who have failed two or more antidepressants. At a $15,000 per treatment course, a 20% market penetration generates $9 billion in peak revenue. The commercial model requires supervised dosing sessions in certified clinics, which limits throughput but also creates a moat against generic competition. Compass is building the infrastructure now, targeting H1 2027 launch if the NDA is approved.

At a $2.0 billion market cap, CMPS is pricing roughly 20% odds of approval against peak sales of $2-4 billion (applying a 3x P/S multiple to the conservative end). If COMP360 is approved, CMPS re-rates to $4-6 billion. If the FDA issues a CRL, the stock drops 60%. The binary is favorable: the clinical data are strong across two Phase 3 trials, the FDA has signaled support through rolling review and the voucher, and big pharma M&A is accelerating into patent cliffs (the patent-cliff M&A targets).

Verdict: Buy. The highest-conviction psychedelics name with two positive Phase 3 trials and an FDA rolling review. Position at 2-3% of a biotech portfolio.

2. Eli Lilly (LLY, $1,174.61, ~$890B market cap): Hold

Catalyst: AtaiBeckley acquisition close Q3 2026; mebufotenin (BPL-003) and DMT (VLS-01) pipeline

Lilly’s $2.8 billion AtaiBeckley acquisition, announced July 17, 2026, is the largest psychedelics deal in history. The lead asset is BPL-003 (mebufotenin benzoate nasal spray), a short-duration 5-MeO-DMT analog for treatment-resistant depression that completed Phase 2. VLS-01 (DMT buccal film) adds a second short-duration tryptamine with a differentiated delivery route. At $6.75 per share plus contingent value rights of up to $2.50, the deal carries a 40% premium to AtaiBeckley’s 30-day VWAP before announcement (the Lilly AtaiBeckley deal analysis; see also 8 biotech takeover targets).

For Lilly shareholders, the acquisition is immaterial: $2.8 billion is 0.3% of Lilly’s $890 billion market cap. The deal is a pipeline signal, not a stock catalyst. Lilly is diversifying beyond GLP-1 obesity drugs into neuroscience, where it already has a presence with donanemab (Alzheimer’s) and lasmiditan (migraine). The psychedelics bet is option value: if BPL-003 or VLS-01 succeeds in Phase 3, Lilly gets a new $1-3 billion neuroscience franchise at a fraction of the cost of an internal development program. If the assets fail, the write-down is absorbable. The stock will not move on psychedelics catalysts; it moves on Mounjaro and Zepbound prescription data and donanemab’s Alzheimer’s market share.

Verdict: Hold. Own LLY for GLP-1, not for psychedelics. The deal validates the sector but does not move the stock.

3. Cybin (CYBN, ~$8.28, ~$750M market cap): Speculative Buy

Catalyst: CYB003 Phase 3 PARADIGM program; Breakthrough Therapy designation

Cybin’s CYB003 is a deuterated psilocybin analog (ClinicalTrials.gov NCT06564818) with Breakthrough Therapy designation for major depressive disorder. The Phase 2 data were compelling: two doses of 16 mg produced a 75% remission rate (MADRS score ≤10) at four months, with a mean MADRS reduction of approximately 22 points from baseline. No drug-related serious adverse events, no suicidal ideation, and no discontinuations. The Phase 3 PARADIGM program is now enrolling across multiple sites with remote, independent, blinded raters.

The deuterated chemistry is the differentiator. By replacing hydrogen with deuterium, Cybin claims improved pharmacokinetics: faster onset, shorter duration, and more predictable metabolism than natural psilocybin. If Phase 3 confirms Phase 2, CYB003 could be a best-in-class psilocybin with a 2-3 hour treatment session versus Compass’s 6-8 hour COMP360 protocol. Shorter sessions mean higher clinic throughput and better economics.

At a $750 million market cap, Cybin is the cheapest way to own the psilocybin thesis. The risk is that Compass gets there first: if COMP360 is approved in 2027, Cybin’s CYB003 launches into an established market. But the shorter-duration profile could win on convenience, and the Breakthrough Therapy designation means the FDA is engaged. Cash of roughly $150 million funds operations into 2027 (see the psychiatry catalysts ranked piece).

Verdict: Speculative Buy. The Phase 2 data are strong and the market cap is small relative to TRD TAM. Position at 1% of a biotech portfolio.

4. AtaiBeckley (ATAI, $7.29, ~$2.7B market cap): Hold

Catalyst: Lilly acquisition at $6.75/share + CVR up to $2.50

AtaiBeckley is in deal limbo. Lilly is paying $6.75 per share in cash at close, expected Q3 2026, plus contingent value rights of up to $2.50 tied to development and regulatory milestones. At $7.29, the stock is trading near the cash offer, implying the market expects the deal to close with modest CVR value. The CVRs are worth something if mebufotenin or DMT hits milestones, but they are binary and illiquid.

There is no independent investment thesis for ATAI at this price. The upside is capped at the deal price plus CVR value (roughly $9.25 if everything hits); the downside is the deal breaks and the stock trades back to its pre-announcement $4.80. Merger arbitrage on a $2.7 billion deal with a 40% premium is not a biotech trade; it is an event-driven trade. Investors looking for psychedelics exposure should own CMPS or CYBN, not ATAI.

Verdict: Hold. The deal arbitrage spread is too narrow to justify the break risk. Own the acquirer (LLY) or the pure-play leaders instead.

5. MindMed (MNMD, ~$14-15, market cap disputed): Avoid

Catalyst: MM-120 LSD for generalized anxiety disorder; Phase 2b data

MindMed is the LSD play in psychedelics, developing MM-120 (lysergide D-tartrate) for generalized anxiety disorder. The Phase 2b data showed a statistically significant reduction in HAM-A scores versus placebo at 12 weeks, but the effect size was modest compared to Compass’s psilocybin data in depression. The company has also struggled with corporate governance: a proxy fight in 2023, management turnover, and a reverse stock split in 2025 to maintain Nasdaq listing.

The market cap situation is unclear. Public data sources show a wide range from $1.5 billion to $6 billion, suggesting potential data quality issues with the stock’s reporting or unusual share structure. For a company at Phase 2b with one asset and a history of governance problems, any market cap above $1 billion is generous. LSD has a longer duration of action than psilocybin (8-12 hours versus 4-6 hours), which makes the commercial model even more challenging: a 12-hour supervised session is not viable at scale.

Verdict: Avoid. The mechanism has commercial viability problems, the governance history is poor, and the market cap is inflated relative to the clinical stage. Wait for Phase 3 data if you must own it.

6. GH Research (GHRS, $27.94, ~$2.0B market cap): Speculative Buy

Catalyst: GH001 inhaled 5-MeO-DMT Phase 2b; FDA clinical hold lifted

GH Research is the 5-MeO-DMT pure play. GH001 is an inhaled formulation of 5-MeO-DMT for treatment-resistant depression, with a Phase 2b trial underway. The FDA lifted a clinical hold on GH001 in 2026, clearing the US regulatory path after an earlier pause related to inhalation device characterization. The stock gained 25% on the hold lift announcement, signaling the market had priced in a significant risk of permanent clinical hold.

The 5-MeO-DMT mechanism is the most intense and shortest-duration psychedelic experience: peak effects last 20-30 minutes with a total session duration under 2 hours, compared to 4-6 hours for psilocybin and 8-12 hours for LSD. This is the commercial advantage: a 2-hour supervised session fits into a clinic schedule like an infusion appointment. GH Research also has GH002, an intranasal formulation in Phase 1, and GH003, a novel intranasal mebufotenin formulation for postpartum depression.

The risk is that the Phase 2b data are not yet public and the FDA hold was only recently lifted. GH001 has not yet demonstrated Phase 3-level efficacy in a large controlled trial. At a $2.0 billion market cap with no Phase 3 data, GHRS is pricing in significant success. The Lilly/AtaiBeckley deal provides a valuation floor: if mebufotenin (a related 5-MeO-DMT analog) was worth $2.8 billion to Lilly, GHRS at $2.0 billion for a pure-play 5-MeO-DMT platform is reasonable by comp. But without Phase 3 data, this is a binary bet on a mechanism that has never been through an FDA approval.

Verdict: Speculative Buy. The 2-hour session is the shortest in the class, and the Lilly comp validates valuation. Wait for Phase 2b data before sizing up.

Risks

The FDA posture is unproven. The Lykos/MDMA CRL in 2024 established that the agency will scrutinize psychedelic trial design (functional unblinding, psychotherapy standardization) more harshly than for small molecules, and no psychedelic has ever been approved. Compass’s rolling review will test this, but until an approval happens, every name trades on regulatory uncertainty. DEA scheduling is unresolved on top of that: psilocybin and MDMA are Schedule I, and rescheduling requires a separate DEA rulemaking process that could take 12-24 months after FDA approval. The commercial model is unproven as well: supervised dosing sessions require trained therapists, certified clinics, and reimbursement codes that do not exist, so the first approved drug has to build the entire delivery infrastructure from scratch.

Verdict

The psychedelics trade is a high-conviction thesis on regulatory normalization and big pharma validation, not on any single clinical data readout. Compass Pathways (CMPS) is the highest-conviction name: two positive Phase 3 trials, NDA rolling review, and a valuation that still prices meaningful approval risk. Cybin (CYBN) is the highest-upside name: strong Phase 2 data, a shorter-duration profile, and a $750 million market cap that leaves room for multiple expansion. GH Research (GHRS) is the second-highest-upside name but riskier: no Phase 3 data yet, but the 5-MeO-DMT mechanism has the shortest session profile (under 2 hours), and the Lilly comp supports valuation. Lilly (LLY) is a Hold; own it for GLP-1, not psychedelics. AtaiBeckley (ATAI) is a merger-arb Hold with limited upside. MindMed (MNMD) is an Avoid. Ranked: CMPS (Buy), CYBN (Speculative Buy), GHRS (Speculative Buy), LLY (Hold), ATAI (Hold), MNMD (Avoid).